Physician profile
Devonne Ortiz
NPI 1376846527
$1,761.22
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $209 · 2023: $784 · 2024: $96.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $689.04 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $228.41 | 2021-2023 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $177.99 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $144.64 | 2021 | |
| Novo Nordisk INC | $141.76 | 2022-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $92.38 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $72.51 | 2023-2024 | Spravato |
| Pfizer INC. | $60.39 | 2021-2024 | |
| Amgen INC. | $37.73 | 2023-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $35.87 | 2023-2024 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $21.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.27 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.59 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.04 | 2023 | Quviviq |
| Eisai INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devonne Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.